½ÃÀ庸°í¼­
»óǰÄÚµå
1575720

¼¼°èÀÇ ÁÖÀÔ ¿ä¹ý ½ÃÀå(2024-2031³â)

Global Infusion Therapy Market - 2024-2031

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: DataM Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® 183 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

º¸°í¼­ °³¿ä

¼¼°è ÁÖÀÔ ¿ä¹ý ½ÃÀåÀº 2023³â 435¾ï ´Þ·¯¿¡ ´ÞÇϰí, 2024-2031³â ¿¹Ãø ±â°£ µ¿¾È ¿¬Æò±Õ 6.8% ¼ºÀåÇÏ¿© 2031³â¿¡´Â 737¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¤¸Æ ³»(IV) ¿ä¹ýÀ̶ó°íµµ ÇÏ´Â ÁÖÀÔ ¿ä¹ýÀº ¹Ù´ÃÀ̳ª Ä«Å×Å͸¦ ÅëÇØ ȯÀÚÀÇ Ç÷·ù¿¡ Á÷Á¢ ¾à¹°, ¾×ü ¹× ¿µ¾çÀ» ÁÖÀÔÇÏ´Â ÀÇ·á ½Ã¼úÀÔ´Ï´Ù. ÀÌ ¹æ¹ýÀº ÁÖ·Î ´Ù¾çÇÑ Áúº´¿¡ ´ëÇÑ Áï°¢ÀûÀ̰í È¿°úÀûÀÎ Ä¡·á¸¦ À§ÇØ »ç¿ëµË´Ï´Ù.

ÁÖÀÔ ¿ä¹ýÀº ƯÈ÷ »ïŰ±â ¾î·Á¿î ȯÀÚ¿¡°Ô °æ±¸¿ë ¾à¹°À» ´ëüÇÒ ¼ö ÀÖ´Â ¾ÈÀüÇÑ Ä¡·á¹ýÀÔ´Ï´Ù. ¶ÇÇÑ À§»êÀ¸·Î ÀÎÇØ ƯÁ¤ ¾à¹°ÀÇ È¿°ú°¡ ¼Õ»óµÇ¾î ¾àÈ¿°¡ ¶³¾îÁú ¼ö ÀÖ´Â °æ¿ì¿¡µµ È¿°úÀûÀÔ´Ï´Ù. ÁÖÀÔ ¿ä¹ýÀº Á¤È®ÇÑ Åõ¾à°ú Áß´Ü ¾ø´Â ¾à¹° Åõ¿©°¡ ÇÊ¿äÇÑ ÁúȯÀ» °ü¸®ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¾à¹°À» Áö¼ÓÀûÀ̰í Á¤È®ÇÏ°Ô Åõ¿©ÇÏ´Â ´É·ÂÀº ´Ù¾çÇÑ °Ç°­ ¹®Á¦¸¦ È¿°úÀûÀ¸·Î Ä¡·áÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù.

½ÃÀå ¿ªÇÐ:

ÃËÁø¿äÀÎ

¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ±â¼úÀÇ ¹ßÀü

¼¼°è ÁÖÀÔ ¿ä¹ý ½ÃÀåÀÇ ¼ö¿ä´Â ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ¿äÀÎ Áß Çϳª´Â ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ±â¼ú ¹ßÀüÀÔ´Ï´Ù. ´ç´¢º´, ¾Ï, ½ÉÇ÷°üÁúȯ°ú °°Àº ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡´Â ÁÖÀÔ ¿ä¹ý ½ÃÀåÀ» Å©°Ô °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áúº´Àº Àå±âÀûÀÎ °ü¸®¿Í Á¤È®ÇÑ ¾à¹°Àü´ÞÀÌ ÇÊ¿äÇÑ °æ¿ì°¡ ¸¹±â ¶§¹®¿¡ ÁÖÀÔ ¿ä¹ýÀÌ Á¡Á¡ ´õ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù.

¼¼°èº¸°Ç±â±¸(WHO)ÀÇ 2024³â ÀÚ·á¿¡ µû¸£¸é, ½ÉÇ÷°ü°è ÁúȯÀº ¸Å³â ¾à 1,790¸¸ ¸íÀÌ »ç¸ÁÇÏ´Â Àü ¼¼°è ÁÖ¿ä »ç¸Á ¿øÀÎÀÔ´Ï´Ù. ÁÖÀÔ ¿ä¹ýÀº ȯÀÚÀÇ ÃÖÀûÀÇ °á°ú¸¦ ¾ò±â À§ÇØ Áö¼ÓÀûÀÎ ¾à¹° Åõ¿©°¡ ÇʼöÀûÀÎ ½ÉºÎÀü°ú °°Àº ÁúȯÀ» °ü¸®ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù.

¼ö¾× ÀåÄ¡ÀÇ Çõ½Å, ƯÈ÷ ÀüÀÚ ÀÇ·á ±â·Ï(EHR)°ú ÅëÇÕÇÏ¿© ½Ç½Ã°£À¸·Î ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ´Â ½º¸¶Æ® ¼ö¾× ÆßÇÁÀÇ °³¹ßÀº ȯÀÚÀÇ ¾ÈÀü°ú Ä¡·á È¿°ú¸¦ Å©°Ô Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ¼ö¾× Ä¡·áÀÇ »óȲÀ» º¯È­½ÃÄÑ º¸´Ù È¿À²ÀûÀÌ°í »ç¿ëÀÚ Ä£È­ÀûÀ¸·Î ¸¸µé°í ÀÖÀ¸¸ç, ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¶ÇÇÑ, ¸¸¼ºÁúȯ¿¡ ´ëÇÑ Çõ½ÅÀûÀÎ Ä¡·á¹ý äÅðú ÷´Ü ¼ÒÇÁÆ®¿þ¾î Ãâ½Ã¿Í °°Àº ¾÷°è ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀüÀÌ ÀÌ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 2¿ù NHS´Â ÇÁ·ÎµÎµµÆÄ¶ó°íµµ ºÒ¸®´Â Æ÷½º ·¹º¸µµÆÄ-Æ÷½ºÄ«ºñµµÆÄ·Î ¾Ë·ÁÁø ÁøÇ༺ ÆÄŲ½¼º´¿¡ ´ëÇÑ »õ·Î¿î Ä¡·áÁ¦¸¦ Ãâ½ÃÇß½À´Ï´Ù. ÀÌ Çõ½ÅÀûÀÎ Ä¡·á¹ýÀº ±âÁ¸ÀÇ °æ±¸¿ë ¾à¹°·Î Áõ»óÀÌ ÃæºÐÈ÷ °³¼±µÇÁö ¾Ê´Â ȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù. ÀÌ Ä¡·áÁ¦´Â ÈÞ´ë¿ë, Âø¿ëÇü Á¤¸ÆÁÖ»ç ½Ã½ºÅÛÀ¸·Î ÇÇÇÏ¿¡ ÀåÂøµÈ ¼ÒÇü ÆßÇÁ¸¦ ÅëÇØ ¾à¹°À» Áö¼ÓÀûÀ¸·Î Åõ¿©ÇÏ¿© 24½Ã°£ µ¿¾È Áõ»óÀ» °ü¸®ÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù.

¶ÇÇÑ 2023³â 6¿ù, B. Braun Medical Inc.´Â ÀÇ·á±â°üÀÇ ¼ö¾× ÆßÇÁ °ü¸®¸¦ °­È­Çϱâ À§ÇÑ Ãֽмö¾× °ü¸® ¼ÒÇÁÆ®¿þ¾îÀÎ DoseTrac Enterprise Infusion Management Software¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ Ã·´Ü ¼ÒÇÁÆ®¿þ¾î´Â ½Ç½Ã°£ ¸ð´ÏÅ͸µ°ú ÈÄÇâÀû º¸°í ±â´ÉÀ» °áÇÕÇÏ¿© ÀÇ·á ±â°üÀÌ ¼ö¾× ÆßÇÁ ¹× °ü·Ã µ¥ÀÌÅÍ¿¡ ´ëÇÑ ´õ ±íÀº ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù.

¾ïÁ¦¿äÀÎ

÷´Ü ±â¼úÀÇ ³ôÀº ºñ¿ë, µð¹ÙÀ̽ºÀÇ À§Çè°ú º¹À⼺, ±ÔÁ¦ ¹× »óȯ ¹®Á¦ µîÀÌ ½ÃÀå ÀúÇØ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­

¼¼°è ÁÖÀÔ ¿ä¹ý ½ÃÀåÀº Á¦Ç° À¯Çü, Åõ¿© °æ·Î, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ ¹× Áö¿ªº°·Î ºÐ·ùµË´Ï´Ù.

¼ö¾× ÆßÇÁ ºÎ¹®Àº ÁÖÀÔ ¿ä¹ý ¼¼°è ½ÃÀå Á¡À¯À²ÀÇ ¾à 52.1%¸¦ Â÷ÁöÇÕ´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È ÁÖÀÔ ÆßÇÁ ºÐ¾ß°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¤È®Çϰí È¿À²ÀûÀÎ ¾à¹°Àü´Þ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÁÖÀÔ ÆßÇÁÀÇ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÁÖÀÔ ÆßÇÁ´Â ȯÀÚ¿¡°Ô ÁÖÀÔ, ¾à¹° ¹× ¿µ¾çÁ¦¸¦ Á¶ÀýµÈ ¿ë·®À¸·Î Åõ¿©Çϱâ À§ÇØ Æ¯º°È÷ ¼³°èµÇ¾úÀ¸¸ç, ´Ù¾çÇÑ ÀÇ·á ÀÀ¿ë ºÐ¾ß¿¡ »ç¿ëµË´Ï´Ù.

¼ö¾× ÆßÇÁ ºÐ¾ß´Â ȯÀÚÀÇ ¾ÈÀü°ú Ä¡·á È¿°ú¸¦ Å©°Ô Çâ»ó½ÃŰ´Â Áö¼ÓÀûÀÎ ±â¼ú ¹ßÀüÀÌ Æ¯Â¡ÀÔ´Ï´Ù. °¡Àå ÁÖ¸ñÇÒ ¸¸ÇÑ ±â¼ú Çõ½Å Áß Çϳª´Â ÀüÀÚ ÀÇ·á ±â·Ï(EHR)°ú ¿øÈ°ÇÏ°Ô ÅëÇյǾî ȯÀÚ µ¥ÀÌÅÍÀÇ ½Ç½Ã°£ ¸ð´ÏÅ͸µÀ» ¿ëÀÌÇÏ°Ô ÇÏ´Â ½º¸¶Æ® ¼ö¾× ÆßÇÁÀÇ °³¹ßÀÔ´Ï´Ù.

ÀüÀÚ ÀÇ·á ±â·Ï(EHR)À» ÅëÇÕÇÑ ½º¸¶Æ® ¼ö¾× ÆßÇÁ´Â Åõ¾à ¿À·ùÀÇ À§ÇèÀ» ÃÖ¼ÒÈ­ÇÏ¿© ȯÀÚ ¾ÈÀüÀ» Å©°Ô Çâ»ó½Ãŵ´Ï´Ù. ÀÌ ±â¼úÀº EHR¿¡¼­ ¼ö¾× ÆßÇÁ·Î Á÷Á¢ Åõ¾à ÁÖ¹®À» ÀÚµ¿À¸·Î Àü¼ÛÇÏ¿© ¼öµ¿ ÇÁ·Î±×·¡¹ÖÀÌ ÇÊ¿äÇÏÁö ¾Ê¾Æ ÀÎÀû ¿À·ùÀÇ °¡´É¼ºÀ» ÁÙÀÔ´Ï´Ù.

¶ÇÇÑ, ÁÖÀÔ ÆßÇÁ ¾÷°è ÁÖ¿ä ±â¾÷ÀÇ Á¦Ç° Ãâ½Ã¿Í ÁÖ¿ä °³¹ßÀÌ ÀÌ ºÎ¹®ÀÇ ½ÃÀå ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 2¿ù Mindray´Â BeneFusion i ½Ã¸®Áî ¹× u ½Ã¸®Áî ÁÖÀÔ ½Ã½ºÅÛÀ» Ãâ½ÃÇÏ¿© ÁÖÀÔ ±â¼úÀÇ È¹±âÀûÀÎ ¹ßÀüÀ» º¸¿©ÁÖ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ±âº»ÀûÀÎ ±â°è ÀåÄ¡¿¡¼­ Åõ¾à ¿À·ù¸¦ ÃÖ¼ÒÈ­Çϰí ȯÀÚ °á°ú¸¦ °³¼±Çϱâ À§ÇØ ¼³°èµÈ Á¤±³ÇÑ ½Ã½ºÅÛÀ¸·Î ÁøÈ­ÇÑ ½º¸¶Æ® ¼ö¾× ÆßÇÁ¸¦ äÅÃÇÏ´Â Ãß¼¼¿Í ÀÏÄ¡ÇÕ´Ï´Ù.

ÀÌź¸ÞµðÄ®Àº 2023³â 4¿ù, Æ÷½ºÆ®Å¥Æ® Äɾî¿Í Ư¼ö ÁÖÀÔ ¿ä¹ýÀ» °­È­Çϱâ À§ÇØ °í¾ÈµÈ ÃÖ÷´Ü ¿¬°áÇü ¿Ü·¡ ¼ö¾× ÆßÇÁÀÎ ¾Æº¸¼Â ¼ö¾× ½Ã½ºÅÛÀ» ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ Çõ½ÅÀûÀÎ ½Ã½ºÅÛÀº ÄÄÆÑÆ®ÇÑ µðÀÚÀΰú ÷´Ü ±â¼úÀ» ÅëÇØ ȯÀÚÀÇ ¾ÈÀü°ú »ç¿ëÀÚ °æÇè Çâ»ó¿¡ ÃÊÁ¡À» ¸ÂÃá Çõ½ÅÀûÀÎ ½Ã½ºÅÛÀÔ´Ï´Ù.

Áö¿ªº° ½ÃÀå ºÐ¼®

ºÏ¹Ì°¡ ÁÖÀÔ ¿ä¹ý ¼¼°è ½ÃÀå Á¡À¯À²ÀÇ ¾à 44.6%¸¦ Â÷ÁöÇÕ´Ï´Ù.

ºÏ¹Ì¿¡¼­´Â ¾Ï, ´ç´¢º´, ½ÉÇ÷°üÁúȯ µî ¸¸¼ºÁúȯÀÇ ¹ßº´·üÀÌ Áõ°¡Çϸ鼭 ÁÖÀÔ ¿ä¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¹Ì±¹¾ÏÇùȸ¿¡ µû¸£¸é 2021³â ¹Ì±¹¿¡¼­ ¾à 190¸¸ ¸íÀÌ »õ·Î ¾Ï Áø´ÜÀ» ¹Þ¾Ò´Ù°í ÇÕ´Ï´Ù. ¾Ï Áø´ÜÀ» ¹ÞÀº ȯÀÚ Áß »ó´ç¼ö´Â È­Çпä¹ý ¹× ±âŸ ÁöÁö ¿ä¹ý µîÀÇ Ä¡·á¸¦ À§ÇØ ÁÖÀÔ ¿ä¹ýÀÌ ÇÊ¿äÇϸç, ÀÌ´Â °ü·Ã Á¦Ç° ¹× ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î À̾îÁö°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ ¹Ì±¹ º´¿øÇùȸ´Â ¹Ì±¹ Àα¸ÀÇ °ÅÀÇ Àý¹Ý¿¡ ÇØ´çÇÏ´Â ¾à 1¾ï 3,300¸¸ ¸íÀÌ °íÇ÷¾Ð, ½ÉÀ庴, °üÀý¿° µî Àû¾îµµ ÇÑ °¡Áö ÀÌ»óÀÇ ¸¸¼ºÁúȯÀ» ¾Î°í ÀÖ´Ù°í ¹àÇû½À´Ï´Ù. ÀÌ ¼ýÀÚ´Â 2030³â±îÁö ¾à 1¾ï 7,000¸¸ ¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ´Â ¸¸¼ºÁúȯÀÌ ¹Ì±¹ ÀÇ·á ½Ã½ºÅÛ¿¡ ¹ÌÄ¡´Â ºÎ´ãÀÌ Áõ°¡Çϰí ÀÖÀ½À» º¸¿©ÁÝ´Ï´Ù.

¶ÇÇÑ, ÀÌ Áö¿ª¿¡´Â ¸¹Àº ÁÖ¿ä ±â¾÷µéÀÌ ÁøÃâÇØ ÀÖ°í, ÀÇ·á ÀÎÇÁ¶ó°¡ Àß °®Ãß¾îÁ® ÀÖÀ¸¸ç, ±â¼ú ¹ßÀüÀÌ ÀÌ·ç¾îÁö°í ÀÖ°í, Á¤ºÎÀÇ ÀçÁ¤ Áö¿ø Á¤Ã¥, ÀçÅà ÀÇ·á ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, Á¦Ç° Ãâ½Ã ¹× ½ÂÀÎ Áõ°¡ µîÀÌ ÀÌ ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¿¹¸¦ µé¾î, ij³ª´Ù¿¡¼­´Â 2024³â 4¿ù ¸ÆÄËÁö Çコ(Mackenzie Health)°¡ BD Alaris EMR Interoperability ½Ã½ºÅÛÀ» ¹ßÇ¥ÇÏ¿© Á¤¸Æ ³» ¾à¹° °ü¸®¿¡ Å« ÁøÀüÀ» ÀÌ·ç¾ú½À´Ï´Ù. ÀÌ Çõ½ÅÀûÀÎ ±â¼úÀº Á¤¸ÆÁÖÀÔ ÆßÇÁ¿Í ȯÀÚÀÇ ÀüÀÚ ÀÇ·á ±â·Ï(EMR)°úÀÇ ¾ç¹æÇâ Åë½ÅÀ» °¡´ÉÇϰÔÇÏ¿© Á¤¸ÆÁÖÀÔ ÇÁ·Î¼¼½º¸¦ °£¼ÒÈ­Çϰí ȯÀÚÀÇ ¾ÈÀüÀ» Çâ»ó½Ãŵ´Ï´Ù.

¶ÇÇÑ 2024³â 4¿ù, ¹Ú½ºÅÍ ÀÎÅͳ»¼Å³ÎÀº Dose IQ Safety Software°¡ žÀçµÈ Novum IQ ´ë¿ë·® ÁÖÀÔ ÆßÇÁ(LVP)¿¡ ´ëÇÑ FDA 510(k) ½ÂÀÎÀ» ȹµæÇß½À´Ï´Ù. ÀÌ Á¦Ç°Àº ÀÌ¹Ì ÁÖ»ç±â ÁÖÀÔ ÆßÇÁ(SYR)¸¦ Æ÷ÇÔÇÑ Novum IQ ÁÖÀÔ Ç÷§Æû¿¡ Ãß°¡µÇ¾î ÀÇ·áÁøÀº ´Ù¾çÇÑ È¯ÀÚ Ä¡·á ȯ°æ¿¡¼­ ÅëÇÕµÈ ½Ã½ºÅÛÀ» »ç¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. »ç¿ëÀÚ °æÇèÀ» °³¼±Çϰí ÀÓ»óÀÇÀÇ ºÒÇÊ¿äÇÑ ¾÷¹« ºÎ´ãÀ» ´ú¾îÁÝ´Ï´Ù. ÀÌ·¯ÇÑ ÅëÇÕÀº ±³À° °úÁ¤À» °£¼ÒÈ­ÇÏ°í ¿©·¯ ÆßÇÁ ½Ã½ºÅÛÀ» °ü¸®ÇÒ ¶§ ¹ß»ýÇÏ´Â ÀÎÁöÀû ºÎ´ãÀ» ÁÙ¿©ÁÝ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå Á¤ÀÇ¿Í °³¿ä

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¸¸¼ºÁúȯ Áõ°¡¿Í ±â¼úÀÇ Áøº¸
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
      • ÷´Ü ±â¼úÀÇ °íºñ¿ë
    • ±âȸ
    • ¿µÇ⠺м®

Á¦5Àå »ê¾÷ ºÐ¼®

  • Porter's Five Forces ºÐ¼®
  • °ø±Þ¸Á ºÐ¼®
  • °¡°Ý ºÐ¼®
  • ±ÔÁ¦ ºÐ¼®

Á¦6Àå Á¦Ç° À¯Çüº°

  • ÁÖÀÔ ÆßÇÁ
  • Á¡Àû ¼¼Æ®
  • Á¡Àû ij´¼¶ó
  • ´Ïµé¸®½º Ä¿³ØÅÍ
  • Á¤¸Æ ¿µ»ó Áø´Ü Àåºñ

Á¦7Àå Åõ¿© °æ·Îº°

  • ±ÙÀ°³»
  • ÇÇÇÏ
  • °æ¸·¿Ü

Á¦8Àå ¿ëµµº°

  • Ç×»ýÁ¦¡¤¹ÙÀÌ·¯½º
  • °­½É¿ä¹ý
  • Ç×ÀÀ°í ¿ä¹ý
  • È­Çпä¹ý
  • ¿µ¾ç¿ä¹ý
  • Ç÷¾× ¼ººÐ
  • ±âŸ

Á¦9Àå ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø¡¤Àü¹® Ŭ¸®´Ð
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • ÀçÅÃÀÇ·á

Á¦10Àå Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ³²¹Ì
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ³²¹Ì
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦11Àå °æÀï »óȲ

  • °æÀï ½Ã³ª¸®¿À
  • ½ÃÀå Æ÷Áö¼Å´×/Á¡À¯À² ºÐ¼®
  • M&A ºÐ¼®

Á¦12Àå ±â¾÷ °³¿ä

  • B. Braun Melsungen AG
    • ±â¾÷ °³¿ä
    • Á¦Ç° Æ÷Æ®Æú¸®¿À¿Í ¼³¸í
    • À繫 °³¿ä
    • ÁÖ¿ä ¹ßÀü
  • ICU Medical, Inc.
  • Baxter International Inc.
  • Fresenius Kabi AG
  • Terumo Corporation
  • Becton, Dickinson and Company
  • Nipro Corporation
  • Mindray Medical India Pvt. Ltd.
  • Moog Inc.
  • Teleflex Incorporated(*LIST NOT EXHAUSTIVE)

Á¦13Àå ºÎ·Ï

ksm 24.11.19

Report Overview

The Global Infusion Therapy Market reached US$ 43.5 billion in 2023 and is expected to reach US$ 73.7 billion by 2031 growing with a CAGR of 6.8% during the forecast period 2024-2031.

Infusion therapy, also known as intravenous (IV) therapy, is a medical procedure that involves delivering medications, fluids, or nutrients directly into a patient's bloodstream through a needle or catheter. This method is primarily used to provide immediate and effective treatment for various medical conditions.

Infusion therapy serves as a safer alternative to oral medication, particularly for patients who have difficulty swallowing. It is also beneficial in situations where stomach acids could compromise the effectiveness of certain medications, rendering them less effective. Infusion therapy is crucial for managing medical conditions that necessitate precise dosing and uninterrupted medication administration. The ability to deliver medications continuously and accurately is vital for effectively treating various health issues.

Market Dynamics: Drivers

Rising prevalence of chronic diseases and technological advancements

The demand for the global infusion therapy market is driven by multiple factors. One of the primary factors is the rising prevalence of chronic diseases and technological advancements. The rising incidence of chronic conditions such as diabetes, cancer, and cardiovascular diseases significantly drives the infusion therapy market. These diseases often require long-term management and precise medication delivery, which makes infusion therapies increasingly essential.

According to the World Health Organization (WHO) data in 2024, indicates that cardiovascular diseases are the leading cause of death worldwide, responsible for approximately 17.9 million fatalities each year. Infusion therapy plays a vital role in managing conditions like heart failure, where continuous medication delivery is essential for achieving optimal patient outcomes.

Innovations in infusion devices, particularly the development of smart infusion pumps that integrate with electronic health records (EHRs) for real-time monitoring, are significantly enhancing patient safety and treatment efficacy. These advancements are transforming the landscape of infusion therapy, making it more efficient and user-friendly, which would propel market growth.

Moreover, key players in the industry's technological advancements such as the introduction of innovative treatments for chronic diseases and launching advanced software propel this market growth. For instance, in February 2024, the NHS launched a new treatment for advanced Parkinson's disease known as foslevodopa-foscarbidopa, also referred to as Produodopa. This innovative therapy is designed for patients whose symptoms are not adequately managed by traditional oral medications. It involves a portable, wearable infusion system that continuously delivers medication through a small pump worn under the skin, allowing for 24-hour symptom management.

Similarly, in June 2023, B. Braun Medical Inc. unveiled its latest infusion management software, DoseTrac Enterprise Infusion Management Software, aimed at enhancing the management of infusion pumps within healthcare organizations. This advanced software provides a combination of real-time monitoring and retrospective reporting capabilities, allowing organizations to gain deeper insights into their infusion pump fleet and the associated data.

Restraints

Factors such as the high cost of advanced technologies, risk & complexity of devices, and regulatory & reimbursement challenges are expected to hamper the market.

Market Segment Analysis

The global infusion therapy market is segmented based on product type, route of administration, application, end-user, and region.

The infusion pumps segment accounted for approximately 52.1% of the global infusion therapy market share

The infusion pumps segment is expected to hold the largest market share over the forecast period. The growing need for accurate and efficient medication delivery systems has led to a rise in the use of infusion pumps. These devices are specifically designed to administer fluids, medications, or nutrients to patients in regulated doses, making them crucial for a wide range of medical applications.

The infusion pumps segment is marked by ongoing technological advancements that significantly enhance patient safety and treatment effectiveness. One of the most notable innovations is the development of smart infusion pumps, which integrate seamlessly with electronic health records (EHRs) to facilitate real-time monitoring of patient data.

Smart infusion pumps with electronic health record (EHR) integration offer a significant improvement in patient safety by minimizing the risk of medication administration errors. This technology allows for the automatic transmission of medication orders directly from the EHR to the infusion pump, eliminating the need for manual programming and reducing the potential for human error.

Moreover, key players in the industry product launches and key developments in the infusion pumps are driving this segment growth in the market. For instance, in February 2023, Mindray launched the BeneFusion i Series and u Series infusion systems marking a significant advancement in infusion technology, emphasizing high precision, adaptive customization, and user-friendly interfaces to enhance medication safety across various clinical settings. This development aligns with the growing trend of adopting smart infusion pumps, which have evolved from basic mechanical devices to sophisticated systems designed to minimize medication errors and improve patient outcomes.

Similarly, in April 2023, Eitan Medical introduced the Avoset Infusion System, a cutting-edge connected ambulatory infusion pump designed to enhance post-acute care and specialty infusion therapy. This innovative system focuses on improving patient safety and user experience through its compact design and advanced technology.

Market Geographical Analysis

North America accounted for approximately 44.6% of the global infusion therapy market share

North America region is expected to hold the largest market share over the forecast period owing to the increasing incidence of chronic diseases such as cancer, diabetes, and cardiovascular conditions significantly driving the demand for infusion therapy in North America.

According to the American Cancer Society, around 1.9 million new cancer cases were diagnosed in the United States in 2021. Many individuals diagnosed with cancer require infusion therapy for treatments such as chemotherapy and other supportive care, which leads to an increased demand for related products and services.

Similarly, American Hospital Association, stated that around 133 million people in the United States, which is nearly half the population, suffer from at least one chronic condition, such as hypertension, heart disease, or arthritis. This number is expected to rise to approximately 170 million by the year 2030, underscoring the increasing burden that chronic diseases place on the healthcare system in the country.

Moreover, in this region, a major number of key player's presence, well-advanced healthcare infrastructure, technological advancements, government favorable reimbursement policies, growing demand for home healthcare services, product launches, and approvals would drive this market growth.

For instance, in April 2024, in Canada, Mackenzie Health's launch of the BD Alaris EMR Interoperability system represents a significant advancement in intravenous (IV) medication management. This innovative technology enables two-way communication between IV infusion pumps and the patient's electronic medical record (EMR), streamlining the infusion process and enhancing patient safety.

Also, in April 2024, Baxter International Inc. received FDA 510(k) clearance for its Novum IQ large volume infusion pump (LVP) equipped with Dose IQ Safety Software. This addition to the Novum IQ Infusion Platform, which already includes a syringe infusion pump (SYR), allows healthcare providers to utilize a unified system across various patient care environments. The Novum IQ platform enhances the user experience by integrating the LVP and SYR pumps, thereby alleviating the workload of non-critical tasks for clinicians. This integration facilitates a streamlined training process and reduces the cognitive load associated with managing multiple pump systems.

Market Segmentation

By Product Type

Infusion Pumps

Intravenous Sets

IV Cannulas

Needleless Connectors

Vein Imaging Devices

By Route of Administration

Intramuscular

Subcutaneous

Epidural

By Application

Antibiotic & Viral

Inotropic Therapy

Anti-coagulation

Chemotherapy

Nutritional Therapy

Blood Component

Others

By End-User

Hospitals & Specialty Clinics

Ambulatory Surgery Centers

Homecare Settings

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

South America

Brazil

Argentina

The rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the infusion therapy market include B. Braun Melsungen AG, ICU Medical, Inc., Baxter International Inc., Fresenius Kabi AG, Terumo Corporation, Becton, Dickinson and Company, Nipro Corporation, Mindray Medical India Pvt. Ltd., Moog Inc., and Teleflex Incorporated among others.

Key Developments

In January 2024, AbbVie launched Produodopa (foslevodopa/foscarbidopa), a continuous subcutaneous infusion therapy, for the treatment of advanced Parkinson's disease in the European Union. Produodopa is the first and only 24-hour levodopa-based subcutaneous infusion therapy approved for this indication in the EU.

In June 2023, Eitan Medical introduced Eitan Insights, a new cloud-based infusion management system tailored for home and specialty infusion needs. This innovative platform connects with Eitan Medical's infusion systems, including the Sapphire pump, which now features a universal plug-and-play cellular accessory called Sapphire Connect, and the Avoset pump, complemented by the AvosetGo app.

Why Purchase the Report?

To visualize the global infusion therapy market segmentation based on product type, route of administration, application, end-user, and region and understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of the infusion therapy market with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping is available in Excel consisting of key products of all the major players.

The global infusion therapy market report would provide approximately 70 tables, 68 figures, and 183 pages

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by Application
  • 3.4. Snippet by End-User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Prevalence of Chronic Diseases and Technological Advancements
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of Advanced Technologies
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. By Product Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index, By Product Type
  • 6.2. Infusion Pumps *
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Intravenous Sets
  • 6.4. IV Cannulas
  • 6.5. Needleless Connectors
  • 6.6. Vein Imaging Devices

7. By Route of Administration

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 7.1.2. Market Attractiveness Index, By Route of Administration
  • 7.2. Intramuscular *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Subcutaneous
  • 7.4. Epidural

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Distribution Channels
  • 8.2. Antibiotic & Viral *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Inotropic Therapy
  • 8.4. Anti-coagulation
  • 8.5. Chemotherapy
  • 8.6. Nutritional Therapy
  • 8.7. Blood Component
  • 8.8. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals & Specialty Clinics *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Ambulatory Surgery Centers
  • 9.4. Homecare Settings

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Spain
      • 10.3.7.5. Italy
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.9. Brazil
    • 10.4.10. Argentina
    • 10.4.11. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. South Korea
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. B. Braun Melsungen AG*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. ICU Medical, Inc.
  • 12.3. Baxter International Inc.
  • 12.4. Fresenius Kabi AG
  • 12.5. Terumo Corporation
  • 12.6. Becton, Dickinson and Company
  • 12.7. Nipro Corporation
  • 12.8. Mindray Medical India Pvt. Ltd.
  • 12.9. Moog Inc.
  • 12.10. Teleflex Incorporated (*LIST NOT EXHAUSTIVE)

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦